Literature DB >> 24698055

Cognitive profiling in relation to short latency afferent inhibition of frontal cortex in multiple system atrophy.

Ozlem Celebi1, Çağrı Mesut Temuçin1, Bulent Elibol1, Esen Saka2.   

Abstract

BACKGROUND: Cognitive dysfunction occurs in multiple system atrophy (MSA) more frequently than previously known. As a type of synucleinopathy, pathology spreads widely in cortical and subcortical areas as the disease advances. The exact anatomical and imaging substrates, and electrophysiological or biochemical indicators of cognitive impairment in MSA are not yet clear. Diminished short-latency afferent inhibition (SAI) of motor cortex was shown to be an electrophysiological correlate of dementia and mild cognitive impairment associated to Parkinson's disease (PD). We hypothesize that it can also be electrophysiological correlate of cognitive impairment in MSA.
METHODS: We studied SAI and a neuropsychological test battery in 19 non-demented MSA patients (11 MSA-P and 8 MSA-C), 10 non-demented PD patients and 10 healthy controls. Neuropsychological test scores were grouped in four main cognitive domains (attention, memory, executive and visuo-spatial functions) and were analyzed by factor analysis.
RESULTS: All subject groups were matched for age. Moreover, the MSA-P, MSA-C, and PD groups were matched for disease duration. Scores of cognitive domains were similar in MSA and PD cases, while scores in attention, executive and visuo-spatial domains were worse in MSA than controls (p < 0.05). SAI was normal in PD but decreased in MSA patients by reaching statistical significance in MSA-C subtype. SAI response was correlated with cognitive performances measured by factor scores of neuropsychological test battery in all study subjects.
CONCLUSIONS: These results show that cognitive functions are impaired in MSA patients compared to controls as well as a parallel reduction in SAI response.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognitive functions; Multiple system atrophy; Parkinson's disease; Short-latency afferent inhibition; Transcranial magnetic stimulation

Mesh:

Year:  2014        PMID: 24698055     DOI: 10.1016/j.parkreldis.2014.03.012

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  5 in total

1.  Transcriptome analysis of grey and white matter cortical tissue in multiple system atrophy.

Authors:  James D Mills; Woojin S Kim; Glenda M Halliday; Michael Janitz
Journal:  Neurogenetics       Date:  2014-11-06       Impact factor: 2.660

2.  Cerebellar atrophy and its contribution to motor and cognitive performance in multiple system atrophy.

Authors:  HuaGuang Yang; Na Wang; XiaoGuang Luo; Hong Lv; Hu Liu; YingMei Li; GuoGuang Fan
Journal:  Neuroimage Clin       Date:  2019-06-06       Impact factor: 4.881

Review 3.  Therapeutic Application of rTMS in Atypical Parkinsonian Disorders.

Authors:  Chrysi Petsani; Athina-Maria Aloizou; Vasileios Siokas; Lambros Messinis; Eleni Peristeri; Christos Bakirtzis; Grigorios Nasios; Efthimios Dardiotis
Journal:  Behav Neurol       Date:  2021-12-23       Impact factor: 3.342

Review 4.  Clinical neurophysiology of Parkinson's disease and parkinsonism.

Authors:  Robert Chen; Alfredo Berardelli; Amitabh Bhattacharya; Matteo Bologna; Kai-Hsiang Stanley Chen; Alfonso Fasano; Rick C Helmich; William D Hutchison; Nitish Kamble; Andrea A Kühn; Antonella Macerollo; Wolf-Julian Neumann; Pramod Kumar Pal; Giulia Paparella; Antonio Suppa; Kaviraja Udupa
Journal:  Clin Neurophysiol Pract       Date:  2022-06-30

5.  Short-latency afferent inhibition and somato-sensory evoked potentials during the migraine cycle: surrogate markers of a cycling cholinergic thalamo-cortical drive?

Authors:  Gianluca Coppola; Davide Di Lenola; Chiara Abagnale; Fabio Ferrandes; Gabriele Sebastianelli; Francesco Casillo; Cherubino Di Lorenzo; Mariano Serrao; Maurizio Evangelista; Jean Schoenen; Francesco Pierelli
Journal:  J Headache Pain       Date:  2020-04-16       Impact factor: 7.277

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.